SINGAPORE, Feb. 21 -- Danish pharmaceutical giant Novo Nordisk has secured a court order to freeze the worldwide assets of Singapore-based KBP Biosciences and its founder Huang Zhenhua, amid a legal battle over an experimental hypertension drug.
The Singapore International Commercial Court granted the order on February 14, following Novo Nordisk's claim that it was misled about the drug's effectiveness, according to a report in The Straits Times yesterday.
The ruling was made public on February 18.
Novo Nordisk, best known for its blockbuster obesity drug Wegovy, is seeking up to US$830 million (RM3.7 billion) in damages and has also initiated legal proceedings against KBP Biosciences in New York, according to the Singapore court.
The D...